Print this page    •   Back to Web version of article

Data Safety Monitoring Board Closes HIV Vaccine Study -- the End of Adenovirus as a Vaccine Vector?

By Paul E. Sax, M.D.

April 29, 2013

On Friday, the NIH announced that HVTN 505, a clinical trial of an HIV vaccine using an adenovirus vector, would be stopped based on a finding of futility by an independent DSMB.

The study had enrolled some 2500 high-risk gay men in the United States. Here are the three key findings leading to this action:

While the difference between the two is numerically but not statistically different, it's clearly in the wrong direction.

Furthermore, it hearkens back to the results of the STEP study -- another HIV vaccine trial using an adenovirus vector, Ad5 -- that demonstrated an increased susceptibility to HIV infection among participants with pre-study immunity to adenovirus. Though HVTN 505 excluded those who had antibodies to Ad5, the results from HVTN 505 suggest that something else might be going on, something related to Ad5 and protective HIV immunity.


(Confession: I have no idea what that might be.)

As with all studies closed by DSMBs, the detailed data analysis starts in earnest now. And though this outcome is clearly disappointing, it will be fascinating to see what the full results show, and most importantly whether we can learn anything about a way forward in this challenging research area.

Paul Sax is Clinical Director of Infectious Diseases at Brigham and Women's Hospital. His blog HIV and ID Observations is part of Journal Watch, where he is Editor-in-Chief of Journal Watch AIDS Clinical Care.

This article was provided by Journal Watch. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.